Market Research Logo

Global Cytomegalovirus (CMV) Therapeutics Market 2019-2023

Global Cytomegalovirus (CMV) Therapeutics Market 2019-2023

About this market

High prevalence of congenital CMV will drive the CMV therapeutics market growth in the forthcoming years. Vendors are increasingly conducting researches to launch novel therapeutics including vaccines that can be administered in newborns. This will also prevent the progression of CMV while catering to the huge unmet need in the market. As a result, the high prevalence of congenital CMV will eventually drive the CMV therapeutics market growth during the next few years. Technavio’s analysts have predicted that the cytomegalovirus (CMV) therapeutics market will register a CAGR of nearly 5% by 2023.

Market Overview

Recurring nature of the disease

One of the growth drivers of the global cytomegalovirus (CMV) therapeutics market is the recurring nature of the disease. The recurring nature of CMV and the potential risk of the indications caused by the disease will significantly increase sales of CMV therapeutics, which will drive the growth of the market.

Asymptomatic nature of the disease

One of the challenges in the growth of the global cytomegalovirus (CMV) therapeutics market is the asymptomatic nature of the disease. The poor diagnosis rate of the disease is expected to hinder the growth of the market during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the cytomegalovirus (CMV) therapeutics market during 2019-2023, view our report.

Competitive Landscape

The market appears to be highly concentrated with the presence of a few market players. Vendors in the market are focusing on developing drugs in more than one form to provide treatment options and ensure the high efficacy of their drugs. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.


Press Release

Technavio Announces the Publication of its Research Report – Global Cytomegalovirus (CMV) Therapeutics Market 2019-2023

Technavio recognizes the following companies as the key players in the global cytomegalovirus (CMV) therapeutics market: AstraZeneca, Bausch Health, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc., and Merck & Co., Inc.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the advent of vaccines.”

According to the report, one of the major drivers for this market is the growing risk factors for CMV.

Further, the report states that one of the major factors hindering the growth of this market is the lack of curative therapies.

Companies Mentioned

AstraZeneca
Bausch Health
F. Hoffmann-La Roche Ltd
Gilead Sciences, Inc.
Merck & Co., Inc.

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: PIPELINE
PART 07: MARKET SEGMENTATION BY ROA
Market segmentation by RoA
Comparison by RoA
Oral - Market size and forecast 2018-2023
Parenteral - Market size and forecast 2018-2023
Others - Market size and forecast 2018-2023
Market opportunity by RoA
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
Competitive scenario
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
AstraZeneca
Bausch Health
F. Hoffmann-La Roche Ltd
Gilead Sciences, Inc.
Merck & Co., Inc.
PART 14: APPENDIX
Research methodology
List of abbreviations
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global CMV therapeutics market pipeline: Overview
Exhibit 18: Global CMV therapeutics market pipeline: Overview
Exhibit 19: RoA - Market share 2018-2023 (%)
Exhibit 20: Comparison by RoA
Exhibit 21: Oral - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Oral - Year-over-year growth 2019-2023 (%)
Exhibit 23: Parenteral - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Parenteral - Year-over-year growth 2019-2023 (%)
Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Others - Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by RoA
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in North America
Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Europe
Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in Asia
Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 42: Top 3 countries in ROW
Exhibit 43: Key leading countries
Exhibit 44: Market opportunity
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: AstraZeneca - Vendor overview
Exhibit 52: AstraZeneca - Product segments
Exhibit 53: AstraZeneca - Organizational developments
Exhibit 54: AstraZeneca - Geographic focus
Exhibit 55: AstraZeneca - Key offerings
Exhibit 56: AstraZeneca - Key customers
Exhibit 57: Bausch Health - Vendor overview
Exhibit 58: Bausch Health - Business segments
Exhibit 59: Bausch Health - Organizational developments
Exhibit 60: Bausch Health - Geographic focus
Exhibit 61: Bausch Health - Segment focus
Exhibit 62: Bausch Health - Key offerings
Exhibit 63: Bausch Health - Key customers
Exhibit 64: F. Hoffmann-La Roche Ltd - Vendor overview
Exhibit 65: F. Hoffmann-La Roche Ltd - Business segments
Exhibit 66: F. Hoffmann-La Roche Ltd - Organizational developments
Exhibit 67: F. Hoffmann-La Roche Ltd - Geographic focus
Exhibit 68: F. Hoffmann-La Roche Ltd - Segment focus
Exhibit 69: F. Hoffmann-La Roche Ltd - Key offerings
Exhibit 70: F. Hoffmann-La Roche Ltd - Key customers
Exhibit 71: Gilead Sciences, Inc. - Vendor overview
Exhibit 72: Gilead Sciences, Inc. - Business segments
Exhibit 73: Gilead Sciences, Inc. - Organizational developments
Exhibit 74: Gilead Sciences, Inc. - Geographic focus
Exhibit 75: Gilead Sciences, Inc. - Key offerings
Exhibit 76: Gilead Sciences, Inc. - Key customers
Exhibit 77: Merck & Co., Inc. - Vendor overview
Exhibit 78: Merck & Co., Inc. - Business segments
Exhibit 79: Merck & Co., Inc. - Organizational developments
Exhibit 80: Merck & Co., Inc. - Geographic focus
Exhibit 81: Merck & Co., Inc. - Segment focus
Exhibit 82: Merck & Co., Inc. - Key offerings
Exhibit 83: Merck & Co., Inc. - Key customers
Exhibit 84: Validation techniques employed for market sizing

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report